|
|
|
|
|
|
Sponsors and Collaborators: |
New Mexico VA Healthcare System Bristol-Myers Squibb |
Information provided by: | New Mexico VA Healthcare System |
ClinicalTrials.gov Identifier: | NCT00567099 |
The purpose of this study is the use of magnetoencephalography or MEG (a machine that measures magnetic activity in your brain) and electroencephalography or EEG (a technique that measures electrical activity in your brain) to study how sounds are processed in individuals with schizophrenia prior to initiation with aripiprazole treatment and after three months of taking the antipsychotic medication aripiprazole.
Condition | Intervention |
Schizophrenia Sensory Gating |
Drug: Aripiprzole |
MedlinePlus related topics: | Schizophrenia |
ChemIDplus related topics: | Aripiprazole |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Active Control, Single Group Assignment |
Official Title: | Remediation of Schizophrenia Sensory Gating Deficit With Aripiprazole |
Estimated Enrollment: | 20 |
Study Start Date: | August 2003 |
Estimated Study Completion Date: | September 2008 |
Dosage form, dosage, frequency and duration:
Aripiprazole 5-30 mg tabs po qday x 3 months
Problems with attention and perception are core features of schizophrenia and are hypothesized to result from defects in the filtering or gating of sensory input. Examination of this requires neuroimaging techniques with high temporal resolution. High-density EEG and MEG in combination with structural magnetic resonance imaging (sMRI) are used to map sensory gating. In a number of recent studies patient treated with novel antipsychotics have been shown to have P50 gating ratios resembling those of normal controls rather than that of schizophrenia subjects treatment with conventional antipsychotics. To date, there is no literature on the effects of aripiprzole on sensory gating. Subjects who meet all inclusion criteria will receive a clinical interview, an MRI, MEG, and neuropsychological testing before starting treatment with aripiprazole and again 3 months later to determine if patients with schizophrenia who are treated with aripiprazole will demonstrate a sensory gating ratio similar to normal controls, indicating no deficit in sensory gating
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Patient Population
Normal Controls
Exclusion Criteria:
Subjects will be excluded from participating in this study if they:
Contact: Billy Jimenez | (505) 265-1711 ext 5117 | billy.jiminez@va.gov |
Contact: Robin R. Douglas, MA, CCRC | (505) 265-1711 ext 5528 | robin.douglas@med.va.gov |
United States, New Mexico | |||||
New Mexico VA Healthcare System | Recruiting | ||||
Albuquerque, New Mexico, United States, 87108 | |||||
Contact: Billy Jimenez 505-265-1711 ext 5117 billy.jimenez@va.gov | |||||
Contact: Robin R. Douglas, MA, CCRC (505) 265-1711 ext 5528 robin.douglas@med.va.gov | |||||
Principal Investigator: Jose M Canive, MD |
New Mexico VA Healthcare System |
Bristol-Myers Squibb |
Principal Investigator: | Jose M Canive, MD | New Mexico VA Healthcare System / BRINM |
Responsible Party: | New Mexico VA Healthcare System ( Jose M. Canive, MD ) |
Study ID Numbers: | 0059, BRINM #150 |
First Received: | December 3, 2007 |
Last Updated: | December 12, 2007 |
ClinicalTrials.gov Identifier: | NCT00567099 |
Health Authority: | United States: Federal Government |
|
|
|
|
|